Literature DB >> 24728512

Afatinib, a lung cancer inhibitor of ErbB family.

Pasqualino de Antonellis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24728512     DOI： 10.1007/s00210-014-0980-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  10 in total

1.  Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.

Authors:  N Weizman; Y Krelin; A Shabtay-Orbach; M Amit; Y Binenbaum; R J Wong; Z Gil
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

Review 2.  EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.

Authors:  Wolfram Brugger; Michael Thomas
Journal:  Lung Cancer       Date:  2012-01-24       Impact factor: 5.705

Review 3.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Authors:  Zhan Yao; Silvia Fenoglio; Ding Cheng Gao; Matthew Camiolo; Brendon Stiles; Trine Lindsted; Michaela Schlederer; Chris Johns; Nasser Altorki; Vivek Mittal; Lukas Kenner; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

5.  Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Authors:  Flavio Solca; Goeran Dahl; Andreas Zoephel; Gerd Bader; Michael Sanderson; Christian Klein; Oliver Kraemer; Frank Himmelsbach; Eric Haaksma; Guenther R Adolf
Journal:  J Pharmacol Exp Ther       Date:  2012-08-10       Impact factor: 4.030

Review 6.  Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Authors:  James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

Authors:  Yu Sun; Judith Campisi; Celestia Higano; Tomasz M Beer; Peggy Porter; Ilsa Coleman; Lawrence True; Peter S Nelson
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

Review 10.  Management of non-small-cell lung cancer: recent developments.

Authors:  Martin Reck; David F Heigener; Tony Mok; Jean-Charles Soria; Klaus F Rabe
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.